Ads
related to: vips stock
Search results
Vipshop (NYSE:VIPS) Price Target Cut to $20.00
ETF DAILY NEWS· 9 hours agoThe firm presently has a “buy” rating on the technology company’s stock. Benchmark cut shares of Vipshop from a “buy” rating to a “hold” rating in a report on Thursday. HSBC ...
Vipshop downgraded to hold by Benchmark amid weak growth outlook By Investing.com
Investing.com· 2 days agoOn Thursday, Benchmark downgraded Vipshop Holdings (NYSE:VIPS) stock from Buy to Hold, following the...
What Do Wall Street Analysts Think About Vipshop Holdings Ltd ADR
Stocks Register· 3 days agoVipshop Holdings Ltd ADR has a market cap of $7.87 billion. With its Forward Dividend at 0.43 and a yield of 2.54%, the company’s investors could be anxious for the VIPS & ...
Vipshop Holdings (NYSE:VIPS) Could Become A Multi-Bagger
Simply Wall St. via Yahoo Finance· 2 days agoSince the stock has returned a staggering 115% to shareholders over the last five years, it looks...
Vipshop Holdings Limited (NYSE:VIPS) Shares Sold by Boston Partners
ETF DAILY NEWS· 6 days agoBoston Partners lowered its position in Vipshop Holdings Limited (NYSE:VIPS – Free Report) by 73.8% in the fourth quarter, according to the company in its most recent disclosure ...
Citi maintains Buy on Vipshop stock despite mixed 1Q24 By Investing.com
Investing.com· 3 days agoOn Wednesday, Citi reaffirmed its Buy rating and $25.00 price target for Vipshop Holdings (NYSE:VIPS...
Earnings call: Vipshop reports mixed Q1 results, plans aggressive SVIP growth By Investing.com
Investing.com· 2 days agoVipshop (NYSE:VIPS) Holdings Limited (NYSE: VIPS) has announced its financial results for the first...
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving...
Benzinga· 3 days agoDyne Therapeutics, Inc . DYN shares fell 3.5% to $31.50 in pre-market trading. Dyne Therapeutics...
Company News for May 23, 2024
Zacks via Yahoo Finance· 2 days agoShares of Vipshop Holdings Limited (VIPS) rose 0.4% after the company reported first-quarter 2024 earnings of $0.65 per share, surpassing the Zacks...
Earnings call: Vivos Therapeutics reports mixed Q1 results, aims for growth By Investing.com
Investing.com· 6 days agoVivos Therapeutics, a company specializing in the treatment of obstructive sleep apnea (OSA),...
